Literature DB >> 20719482

[French guidelines for sweat test practice and interpretation for cystic fibrosis neonatal screening].

I Sermet-Gaudelus1, A Munck, M Rota, M Roussey, D Feldmann, T Nguyen-Khoa.   

Abstract

These guidelines aim to standardize the standard operating procedures for the sweat test in newborn cystic fibrosis (CF) screening. They have been implemented by the national Neonatal Screening working group of the French Federation for Cystic Fibrosis. It is recommended that the sweat test be performed when the infant weighs more than 3 kg and is at least 3 weeks of age. Sweat gland secretion is stimulated by transdermal administration of pilocarpine by iontophoresis. Sweat is preferentially collected in a Macroduct coil. Diagnosis of CF is based on the sweat chloride level. A sweat chloride level below 30 mmol/l very probably rules out CF; 60 mmol/l or higher supports the diagnosis of CF. Values between 30 and 60 mmol/l are considered abnormal.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20719482     DOI: 10.1016/j.arcped.2010.06.021

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  4 in total

1.  Sweat test practice in pediatric pulmonology after introduction of cystic fibrosis newborn screening.

Authors:  Céline Grimaldi; François Brémont; Michèle Berlioz-Baudoin; Jacques Brouard; Harriet Corvol; Laure Couderc; Guillaume Lezmi; Isabelle Pin; Isabelle Petit; Philippe Reix; Natacha Remus; Cyril Schweitzer; Caroline Thumerelle; Jean-Christophe Dubus
Journal:  Eur J Pediatr       Date:  2015-06-16       Impact factor: 3.183

2.  Sweat chloride quantification using capillary electrophoresis.

Authors:  Patricia Dubot; Jing Liang; Jacobé Dubs; Yohann Missiak; Cédric Sarazin; François Couderc; Elizabeth Caussé
Journal:  Pract Lab Med       Date:  2018-12-07

3.  Comprehensive CFTR gene analysis of the French cystic fibrosis screened newborn cohort: implications for diagnosis, genetic counseling, and mutation-specific therapy.

Authors:  Marie Pierre Audrézet; Anne Munck; Virginie Scotet; Mireille Claustres; Michel Roussey; Dominique Delmas; Claude Férec; Marie Desgeorges
Journal:  Genet Med       Date:  2014-08-14       Impact factor: 8.822

4.  Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data.

Authors:  Frank J Accurso; Fredrick Van Goor; Jiuhong Zha; Anne J Stone; Qunming Dong; Claudia L Ordonez; Steven M Rowe; John Paul Clancy; Michael W Konstan; Heather E Hoch; Sonya L Heltshe; Bonnie W Ramsey; Preston W Campbell; Melissa A Ashlock
Journal:  J Cyst Fibros       Date:  2014-03       Impact factor: 5.527

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.